Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Disease × 3-Iodobenzylguanidine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Neuroblastoma 3 Pheochromocytoma 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Ganglioneuroblastoma 1 Disease 1

Interventions

Magnetic Resonance Spectroscopy 3 Positron-Emission Tomography 2 Lenalidomide 2 Injections 2 Dexamethasone 2 fluciclovine F-18 1 Thalidomide 1 Prednisone 1 Mitomycin 1 Melphalan 1 Diagnosis 1 Cyclophosphamide 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00126412 2019-05-31

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

GE Healthcare

Phase 3 Completed

Disease, Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡